Biocon Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 16, 2025, 11:19 pm

Market Cap	39,464 Cr.
Current Price	329
High / Low	405/260
Stock P/E	47.9
Book Value	175
Dividend Yield	0.15 %
ROCE	5.96 %
ROE	5.25 %
Face Value	5.00
PEG Ratio	28.82

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Biocon Ltd

Competitors of Biocon Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	155 Cr.	110	247/84.3	22.4	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.77 Cr.	3.02	4.33/2.75		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	45.4 Cr.	61.2	94.9/44.5	15.4	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.2 Cr.	24.0	29.0/12.3	35.9	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	17,552.45 Cr	1,110.30		43.07	182.59	0.34%	16.00%	16.30%	6.24

All Competitor Stocks of Biocon Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	2,174	2,409	2,140	2,320	2,941	3,774	3,423	3,462	3,954	3,917	3,433	3,590	3,821
Expenses	1,733	1,870	1,783	1,877	2,352	2,817	2,741	2,745	3,051	3,004	2,812	2,905	3,070
Operating Profit	441	539	356	442	589	957	681	717	903	913	620	685	752
OPM %	20%	22%	17%	19%	20%	25%	20%	21%	23%	23%	18%	19%	20%
Other Income	48	26	78	48	-193	152	94	134	587	40	1,166	58	53
Interest	15	10	20	30	120	249	233	248	267	227	236	226	223
Depreciation	206	212	218	231	301	364	358	389	414	407	405	420	425
Profit before tax	269	342	197	229	-26	497	184	214	808	319	1,146	98	156
Tax %	18%	17%	15%	64%	-19%	17%	19%	19%	7%	30%	25%	72%	48%
Net Profit	220	284	167	82	-21	414	149	173	753	223	862	27	81
EPS in Rs	1.56	1.99	1.20	0.39	-0.35	2.61	0.84	1.05	5.50	1.13	5.49	-0.13	0.21

Last Updated: March 3, 2025, 5:13 pm

Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 3,821.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,590.00 Cr. (Sep 2024) to 3,821.00 Cr., marking an increase of 231.00 Cr..
For Expenses, as of Dec 2024, the value is 3,070.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,905.00 Cr. (Sep 2024) to 3,070.00 Cr., marking an increase of 165.00 Cr..
For Operating Profit, as of Dec 2024, the value is 752.00 Cr.. The value appears strong and on an upward trend. It has increased from 685.00 Cr. (Sep 2024) to 752.00 Cr., marking an increase of 67.00 Cr..
For OPM %, as of Dec 2024, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Sep 2024) to 20.00%, marking an increase of 1.00%.
For Other Income, as of Dec 2024, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Sep 2024) to 53.00 Cr., marking a decrease of 5.00 Cr..
For Interest, as of Dec 2024, the value is 223.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 226.00 Cr. (Sep 2024) to 223.00 Cr., marking a decrease of 3.00 Cr..
For Depreciation, as of Dec 2024, the value is 425.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 420.00 Cr. (Sep 2024) to 425.00 Cr., marking an increase of 5.00 Cr..
For Profit before tax, as of Dec 2024, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Sep 2024) to 156.00 Cr., marking an increase of 58.00 Cr..
For Tax %, as of Dec 2024, the value is 48.00%. The value appears to be improving (decreasing) as expected. It has decreased from 72.00% (Sep 2024) to 48.00%, marking a decrease of 24.00%.
For Net Profit, as of Dec 2024, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Sep 2024) to 81.00 Cr., marking an increase of 54.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.21. The value appears strong and on an upward trend. It has increased from -0.13 (Sep 2024) to 0.21, marking an increase of 0.34.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:49 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	2,485	2,877	3,090	3,347	3,891	4,123	5,514	6,300	7,143	8,184	11,174	14,756	14,762
Expenses	1,942	2,190	2,394	2,957	2,912	3,294	4,121	4,725	5,562	6,391	8,762	11,540	11,791
Operating Profit	543	687	696	390	980	829	1,394	1,575	1,581	1,793	2,412	3,216	2,971
OPM %	22%	24%	23%	12%	25%	20%	25%	25%	22%	22%	22%	22%	20%
Other Income	255	56	158	639	173	228	340	228	260	72	18	853	1,318
Interest	8	2	9	29	26	62	71	65	58	68	419	974	912
Depreciation	179	204	221	249	277	385	448	552	715	814	1,113	1,569	1,658
Profit before tax	610	538	624	751	850	610	1,215	1,186	1,068	983	897	1,525	1,719
Tax %	16%	20%	15%	19%	19%	26%	17%	27%	21%	22%	28%	15%
Net Profit	513	431	528	609	688	453	1,003	871	846	772	643	1,298	1,193
EPS in Rs	4.24	3.45	4.14	4.59	5.10	3.10	7.54	6.24	6.17	5.40	3.85	8.52	6.70
Dividend Payout %	29%	24%	20%	18%	10%	16%	7%	0%	0%	9%	39%	6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-15.98%	22.51%	15.34%	12.97%	-34.16%	121.41%	-13.16%	-2.87%	-8.75%	-16.71%	101.87%
Change in YoY Net Profit Growth (%)	0.00%	38.49%	-7.16%	-2.37%	-47.13%	155.57%	-134.57%	10.29%	-5.88%	-7.96%	118.58%

Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	18%
5 Years:	22%
3 Years:	27%
TTM:	1%

Compounded Profit Growth
10 Years:	9%
5 Years:	6%
3 Years:	11%
TTM:	-31%

Stock Price CAGR
10 Years:	16%
5 Years:	-1%
3 Years:	-1%
1 Year:	24%

Return on Equity
10 Years:	8%
5 Years:	7%
3 Years:	6%
Last Year:	5%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:35 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	100	100	100	100	100	300	300	600	600	600	600	600	600
Reserves	2,595	2,927	3,171	3,934	4,738	4,881	5,798	6,106	7,027	7,832	17,267	19,183	20,393
Borrowings	267	864	1,117	2,478	2,302	2,264	2,422	2,715	4,481	5,147	18,019	16,277	16,771
Other Liabilities	1,454	1,860	1,988	1,947	2,254	2,545	3,672	4,993	6,382	6,763	15,856	19,693	19,364
Total Liabilities	4,416	5,751	6,375	8,458	9,394	9,990	12,192	14,414	18,490	20,342	51,742	55,753	57,128
Fixed Assets	1,510	1,525	1,630	1,748	3,626	3,700	4,471	5,971	6,364	6,569	29,468	30,644	34,792
CWIP	312	1,206	1,677	2,240	839	1,303	1,899	2,196	2,800	4,110	7,317	7,993	4,354
Investments	587	765	230	902	1,253	675	1,012	966	1,952	1,588	2,069	1,000	1,809
Other Assets	2,007	2,255	2,839	3,569	3,676	4,312	4,811	5,281	7,374	8,074	12,888	16,117	16,174
Total Assets	4,416	5,751	6,375	8,458	9,394	9,990	12,192	14,414	18,490	20,342	51,742	55,753	57,128

Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹600.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 600.00 Cr..
For Reserves, as of Sep 2024, the value is ₹20,393.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,183.00 Cr. (Mar 2024) to ₹20,393.00 Cr., marking an increase of 1,210.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹16,771.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 16,277.00 Cr. (Mar 2024) to ₹16,771.00 Cr., marking an increase of 494.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹19,364.00 Cr.. The value appears to be improving (decreasing). It has decreased from 19,693.00 Cr. (Mar 2024) to ₹19,364.00 Cr., marking a decrease of 329.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹57,128.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 55,753.00 Cr. (Mar 2024) to ₹57,128.00 Cr., marking an increase of 1,375.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹34,792.00 Cr.. The value appears strong and on an upward trend. It has increased from 30,644.00 Cr. (Mar 2024) to ₹34,792.00 Cr., marking an increase of 4,148.00 Cr..
For CWIP, as of Sep 2024, the value is ₹4,354.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,993.00 Cr. (Mar 2024) to ₹4,354.00 Cr., marking a decrease of 3,639.00 Cr..
For Investments, as of Sep 2024, the value is ₹1,809.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,000.00 Cr. (Mar 2024) to ₹1,809.00 Cr., marking an increase of 809.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹16,174.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,117.00 Cr. (Mar 2024) to ₹16,174.00 Cr., marking an increase of 57.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹57,128.00 Cr.. The value appears strong and on an upward trend. It has increased from 55,753.00 Cr. (Mar 2024) to ₹57,128.00 Cr., marking an increase of 1,375.00 Cr..

Notably, the Reserves (20,393.00 Cr.) exceed the Borrowings (16,771.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	471	561	211	371	640	662	1,155	1,283	1,160	1,177	1,852	2,954
Cash from Investing Activity +	-358	-904	-491	-1,138	-510	-684	-703	-1,505	-3,651	-1,662	-14,260	-1,002
Cash from Financing Activity +	-9	426	186	1,068	-178	-240	-242	388	2,564	242	13,049	-2,333
Net Cash Flow	105	83	-94	300	-47	-261	210	165	72	-243	641	-380

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	276.00	-177.00	695.00	388.00	978.00	827.00	-1.00	-1.00	-3.00	-4.00	-16.00	-13.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	75	76	91	78	83	94	86	71	77	92	117	154
Inventory Days	139	116	132	153	160	161	199	263	304	309	423	368
Days Payable	121	107	125	172	187	224	231	243	246	216	383	467
Cash Conversion Cycle	93	85	98	59	57	31	53	91	134	184	157	55
Working Capital Days	21	-0	12	31	34	18	15	8	80	112	85	2
ROCE %	15%	15%	12%	9%	12%	8%	13%	12%	10%	9%	6%	6%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%
FIIs	15.74%	16.00%	15.62%	16.31%	15.79%	14.42%	10.20%	9.52%	7.97%	6.55%	5.63%	5.90%
DIIs	7.44%	7.37%	8.36%	7.72%	7.76%	8.63%	11.89%	12.59%	14.08%	14.51%	13.69%	14.29%
Public	15.46%	15.34%	14.76%	14.60%	15.17%	15.74%	16.70%	16.77%	16.92%	17.96%	19.74%	18.90%
Others	0.72%	0.65%	0.63%	0.73%	0.63%	0.58%	0.55%	0.49%	0.39%	0.33%	0.32%	0.28%
No. of Shareholders	3,63,447	3,64,502	3,47,911	3,41,016	3,69,816	3,91,382	4,11,086	4,12,441	4,15,046	4,34,339	4,70,261	4,43,513

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
SBI Contra Fund	16,770,774	1.83	463.71	16,770,774	2025-04-16	0%
Mirae Asset Large Cap Fund	10,709,389	0.79	296.11	N/A	N/A	N/A
SBI Balanced Advantage Fund	10,021,205	0.99	277.09	10,021,205	2025-04-14	0%
Quant Flexi Cap Fund	5,611,098	3.73	155.15	N/A	N/A	N/A
Quant Mid Cap Fund	4,100,000	2.09	113.37	N/A	N/A	N/A
Kotak Equity Arbitrage Fund - Regular Plan	4,025,000	0.28	111.29	4,025,000	2025-04-14	0%
SBI Arbitrage Opportunities Fund	3,397,500	0.34	93.94	N/A	N/A	N/A
ICICI Prudential India Opportunities Fund	3,114,146	0.5	86.11	3,114,146	2025-04-12	0%
Sundaram Mid Cap Fund	3,080,023	0.83	85.16	3,080,023	2025-04-14	0%
Sundaram Mid Cap Fund - Institutional Plan	3,080,023	0.83	85.16	N/A	N/A	N/A

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	8.55	3.88	5.44	6.24	6.32
Diluted EPS (Rs.)	8.54	3.87	5.42	6.19	6.30
Cash EPS (Rs.)	24.58	16.02	14.93	13.59	11.86
Book Value[Excl.RevalReserv]/Share (Rs.)	210.51	187.31	78.87	70.09	61.52
Book Value[Incl.RevalReserv]/Share (Rs.)	210.52	187.31	78.88	70.10	61.53
Revenue From Operations / Share (Rs.)	122.90	93.07	68.17	59.22	52.50
PBDIT / Share (Rs.)	34.68	24.05	18.18	15.89	14.70
PBIT / Share (Rs.)	21.62	14.78	11.40	9.93	10.10
PBT / Share (Rs.)	13.40	8.86	9.91	9.56	10.12
Net Profit / Share (Rs.)	11.51	6.75	8.15	7.63	7.26
NP After MI And SOA / Share (Rs.)	8.52	3.85	5.40	6.17	6.24
PBDIT Margin (%)	28.22	25.84	26.67	26.83	28.00
PBIT Margin (%)	17.58	15.88	16.72	16.77	19.24
PBT Margin (%)	10.90	9.52	14.54	16.14	19.28
Net Profit Margin (%)	9.36	7.24	11.95	12.88	13.82
NP After MI And SOA Margin (%)	6.92	4.14	7.92	10.42	11.87
Return on Networth / Equity (%)	5.16	2.58	7.69	9.83	11.15
Return on Capital Employeed (%)	6.37	4.07	8.26	8.32	11.61
Return On Assets (%)	1.82	0.88	3.17	3.99	5.18
Long Term Debt / Equity (X)	0.65	0.85	0.47	0.39	0.18
Total Debt / Equity (X)	0.79	0.99	0.58	0.47	0.28
Asset Turnover Ratio (%)	0.27	0.30	0.12	0.17	0.19
Current Ratio (X)	0.98	1.45	2.19	1.81	1.33
Quick Ratio (X)	0.66	0.95	1.59	1.36	0.97
Inventory Turnover Ratio (X)	1.10	0.97	0.75	0.81	1.10
Dividend Payout Ratio (NP) (%)	17.61	12.96	0.00	0.00	8.42
Dividend Payout Ratio (CP) (%)	6.95	3.80	0.00	0.00	4.84
Earning Retention Ratio (%)	82.39	87.04	0.00	0.00	91.58
Cash Earning Retention Ratio (%)	93.05	96.20	0.00	0.00	95.16
Interest Coverage Ratio (X)	4.27	6.89	32.29	33.05	27.19
Interest Coverage Ratio (Post Tax) (X)	2.43	3.63	17.12	16.82	13.82
Enterprise Value (Cr.)	50669.85	44766.88	44360.07	51477.10	34040.50
EV / Net Operating Revenue (X)	3.43	4.01	5.42	7.24	5.40
EV / EBITDA (X)	12.17	15.50	20.32	26.99	19.29
MarketCap / Net Operating Revenue (X)	2.15	2.22	4.91	6.90	5.15
Retention Ratios (%)	82.38	87.03	0.00	0.00	91.57
Price / BV (X)	1.60	1.39	4.76	6.51	4.84
Price / Net Operating Revenue (X)	2.15	2.22	4.91	6.90	5.15
EarningsYield	0.03	0.01	0.01	0.01	0.02

After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is 8.55. This value is within the healthy range. It has increased from 3.88 (Mar 23) to 8.55, marking an increase of 4.67.
For Diluted EPS (Rs.), as of Mar 24, the value is 8.54. This value is within the healthy range. It has increased from 3.87 (Mar 23) to 8.54, marking an increase of 4.67.
For Cash EPS (Rs.), as of Mar 24, the value is 24.58. This value is within the healthy range. It has increased from 16.02 (Mar 23) to 24.58, marking an increase of 8.56.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.51. It has increased from 187.31 (Mar 23) to 210.51, marking an increase of 23.20.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.52. It has increased from 187.31 (Mar 23) to 210.52, marking an increase of 23.21.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 122.90. It has increased from 93.07 (Mar 23) to 122.90, marking an increase of 29.83.
For PBDIT / Share (Rs.), as of Mar 24, the value is 34.68. This value is within the healthy range. It has increased from 24.05 (Mar 23) to 34.68, marking an increase of 10.63.
For PBIT / Share (Rs.), as of Mar 24, the value is 21.62. This value is within the healthy range. It has increased from 14.78 (Mar 23) to 21.62, marking an increase of 6.84.
For PBT / Share (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 8.86 (Mar 23) to 13.40, marking an increase of 4.54.
For Net Profit / Share (Rs.), as of Mar 24, the value is 11.51. This value is within the healthy range. It has increased from 6.75 (Mar 23) to 11.51, marking an increase of 4.76.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 8.52. This value is within the healthy range. It has increased from 3.85 (Mar 23) to 8.52, marking an increase of 4.67.
For PBDIT Margin (%), as of Mar 24, the value is 28.22. This value is within the healthy range. It has increased from 25.84 (Mar 23) to 28.22, marking an increase of 2.38.
For PBIT Margin (%), as of Mar 24, the value is 17.58. This value is within the healthy range. It has increased from 15.88 (Mar 23) to 17.58, marking an increase of 1.70.
For PBT Margin (%), as of Mar 24, the value is 10.90. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 10.90, marking an increase of 1.38.
For Net Profit Margin (%), as of Mar 24, the value is 9.36. This value is within the healthy range. It has increased from 7.24 (Mar 23) to 9.36, marking an increase of 2.12.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 6.92. This value is below the healthy minimum of 8. It has increased from 4.14 (Mar 23) to 6.92, marking an increase of 2.78.
For Return on Networth / Equity (%), as of Mar 24, the value is 5.16. This value is below the healthy minimum of 15. It has increased from 2.58 (Mar 23) to 5.16, marking an increase of 2.58.
For Return on Capital Employeed (%), as of Mar 24, the value is 6.37. This value is below the healthy minimum of 10. It has increased from 4.07 (Mar 23) to 6.37, marking an increase of 2.30.
For Return On Assets (%), as of Mar 24, the value is 1.82. This value is below the healthy minimum of 5. It has increased from 0.88 (Mar 23) to 1.82, marking an increase of 0.94.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.65. This value is within the healthy range. It has decreased from 0.85 (Mar 23) to 0.65, marking a decrease of 0.20.
For Total Debt / Equity (X), as of Mar 24, the value is 0.79. This value is within the healthy range. It has decreased from 0.99 (Mar 23) to 0.79, marking a decrease of 0.20.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has decreased from 0.30 (Mar 23) to 0.27, marking a decrease of 0.03.
For Current Ratio (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.45 (Mar 23) to 0.98, marking a decrease of 0.47.
For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 23) to 0.66, marking a decrease of 0.29.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.10. This value is below the healthy minimum of 4. It has increased from 0.97 (Mar 23) to 1.10, marking an increase of 0.13.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 17.61. This value is below the healthy minimum of 20. It has increased from 12.96 (Mar 23) to 17.61, marking an increase of 4.65.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.95. This value is below the healthy minimum of 20. It has increased from 3.80 (Mar 23) to 6.95, marking an increase of 3.15.
For Earning Retention Ratio (%), as of Mar 24, the value is 82.39. This value exceeds the healthy maximum of 70. It has decreased from 87.04 (Mar 23) to 82.39, marking a decrease of 4.65.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.05. This value exceeds the healthy maximum of 70. It has decreased from 96.20 (Mar 23) to 93.05, marking a decrease of 3.15.
For Interest Coverage Ratio (X), as of Mar 24, the value is 4.27. This value is within the healthy range. It has decreased from 6.89 (Mar 23) to 4.27, marking a decrease of 2.62.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.43. This value is below the healthy minimum of 3. It has decreased from 3.63 (Mar 23) to 2.43, marking a decrease of 1.20.
For Enterprise Value (Cr.), as of Mar 24, the value is 50,669.85. It has increased from 44,766.88 (Mar 23) to 50,669.85, marking an increase of 5,902.97.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 23) to 3.43, marking a decrease of 0.58.
For EV / EBITDA (X), as of Mar 24, the value is 12.17. This value is within the healthy range. It has decreased from 15.50 (Mar 23) to 12.17, marking a decrease of 3.33.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
For Retention Ratios (%), as of Mar 24, the value is 82.38. This value exceeds the healthy maximum of 70. It has decreased from 87.03 (Mar 23) to 82.38, marking a decrease of 4.65.
For Price / BV (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.39 (Mar 23) to 1.60, marking an increase of 0.21.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Biocon Ltd as of April 17, 2025 is: 352.59

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 17, 2025, Biocon Ltd is Undervalued by 7.17% compared to the current share price 329.00

Intrinsic Value of Biocon Ltd as of April 17, 2025 is: 358.45

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 17, 2025, Biocon Ltd is Undervalued by 8.95% compared to the current share price 329.00

Last 5 Year EPS CAGR: 1.66%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (8,142.46 cr) compared to borrowings (5,778.77 cr), indicating strong financial stability. The company has shown consistent growth in sales (6.31 cr) and profit (451.38 cr) over the years.	The stock has a low average ROCE of 10.58%, which may not be favorable. The stock has a high average Working Capital Days of 34.83, which may not be favorable. The stock has a high average Cash Conversion Cycle of 91.42, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
1. Net Profit Margin: 9.36%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 6.37% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 5.16% (Industry Average ROE: 16.3%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.43
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.66
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 47.9 (Industry average Stock P/E: 43.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.79
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 2127.30 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	20th K.M. Hosur Road, Bengaluru Karnataka 560100	investor.relations@biocon.com http://www.biocon.com

Management
Name	Position Held
Ms. Kiran Mazumdar Shaw	Executive Chairperson
Mr. Siddharth Mittal	Managing Director & CEO
Prof. Ravi Rasendra Mazumdar	Non Exe.Non Ind.Director
Mr. Eric Vivek Mazumdar	Non Exe.Non Ind.Director
Mr. Meleveetil Damodaran	Lead Independent Director
Dr. Vijay Kumar Kuchroo	Independent Director
Mr. Bobby Kanubhai Parikh	Independent Director
Mr. Peter John Bains	Independent Director
Mr. Naina Lal Kidwai	Independent Director

FAQ

What is the intrinsic value of Biocon Ltd?

Biocon Ltd's intrinsic value (as of 17 April 2025) is ₹352.59 — 7.17% higher the current market price of 329.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 39,464 Cr. market cap, FY2025-2026 high/low of ₹405/260, reserves of 20,393 Cr, and liabilities of 57,128 Cr.

What is the Market Cap of Biocon Ltd?

The Market Cap of Biocon Ltd is 39,464 Cr..

What is the current Stock Price of Biocon Ltd as on 17 April 2025?

The current stock price of Biocon Ltd as on 17 April 2025 is 329.

What is the High / Low of Biocon Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Biocon Ltd stocks is ₹405/260.

What is the Stock P/E of Biocon Ltd?

The Stock P/E of Biocon Ltd is 47.9.

What is the Book Value of Biocon Ltd?

The Book Value of Biocon Ltd is 175.

What is the Dividend Yield of Biocon Ltd?

The Dividend Yield of Biocon Ltd is 0.15 %.

What is the ROCE of Biocon Ltd?

The ROCE of Biocon Ltd is 5.96 %.

What is the ROE of Biocon Ltd?

The ROE of Biocon Ltd is 5.25 %.

What is the Face Value of Biocon Ltd?

The Face Value of Biocon Ltd is 5.00.